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We examined SARS-CoV-2 (Covid-19) available treatments and pro-
phylactic methods that included interventions associated with inhibiting 
the “type II transmembrane serine protease” (TMPRSS2) to limit the 
fusion between the Covid-19 Spike proteins and ACE2 receptors, or 
newly developed therapeutics like Remdesivir that interferes with the 
viral RNA replication. We explored the dilemma of ACE2 receptors that 
have a protective function against high blood pressure associated disor-
ders, yet, they serve as the viral points of entry, elevating the probability 
of infection. Human tissues’ analysis reveals a higher ACE2 expression 
in adipose tissue, placing obesity-related conditions in the eye of the 
pandemic storm. It primarily exposes males due to the surge of ACE2 re-
ceptors in the testes along with other tissues. Males manifest a relatively 
higher positive ACE2 correlations with certain immune cells in the lungs, 
thyroid, adrenals, liver and colon, while females evidence higher ACE2 
correlations with immune cells in the heart. The remaining tissues’ ACE2/
immunity expressions are equivalent in both sexes, indicating that despite 
its preference for males, the threat of Covid-19 can easily target females. 
Recent reports indicate that Covid-19 is empowered by hindering the 
critical process of viral recognition during the adaptive immune response 
leading to the “cytokine storm”, the aggravated immune response that 
indiscriminately perseveres, rampaging the host’s vital organs. Sedentary 
lifestyle, age-related hormonal imbalance, and adiposity induced inflam-
mation predispose the body to the immune collapse following Covid-19 
invasion, spotlighting the detrimental aftermath of metabolic dysfunction, 
and excess food consumption provoked by elevated cortisol and dysreg-
ulated appetite hormones. ACE 2 expression is suppressed in the skeletal 
muscle, rendering fitness and weight management an effective Covid-19 
preventive intervention, along with social distancing, hygiene, and facial 
coverings. Physical activity, or exercise alternative methods have recent-
ly demonstrated statistically significant reductions of the inflammatory 
marker C-Reactive Protein (CRP), triglycerides, visceral fat, cortisol and 
the orexigenic hormone ghrelin, juxtaposed by optimal increases of IGF-
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1. Introduction
The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) related to the Coronavirus dis-ease 2019 (Covid-19) is currently recognized as 
a global health crisis. In a way, it resembles the initially 
unforeseen results of the David and Goliath battle, the vi-
rus against all our medical advances, ultimately leading to 
devastating consequences that range from lockdowns and 
economic disruption to family and personal tragedies with 
over a million deaths worldwide.
The purpose of this review was to analyse the six prima-
ry strategies currently available in the prevention and treat-
ment of SARS-CoV-2: (1) Inhibit the “type II transmem-
brane serine protease” (TMPRSS2) that primes both ACE2 
receptors and the Covid’s Spike (S1, S2) glycoproteins to 
facilitate their fusion. (2) Increase shedding of the ACE2 
receptors, induced by “A Disintegrin And Metalloprotease 
17” (ADAM17) that may potentially restrict the spread of 
the disease. (3) Obstruct the action of the Nucleocaspic (N) 
protein involved in the replication of the viral DNA. (4) 
Prophylactic measures or techniques to harness the rampag-
ing inflammatory response leading to the “cytokine storm” 
that promotes high mortality rates. (5) Protect against in-
fection with increased hygiene, face coverings and social 
distancing. (6) Capitalize on wellbeing via a lifestyle that 
promotes optimal weight, fitness and hormonal balance to 
prevent and/or defend against infection. 
2. The Dilemma of Ang II and ACE2 Receptors
The imminent fusion between Covid-19 Spike (S) proteins 
and angiotensin enzyme-2 (ACE2) receptors preludes the 
viral entry into human cells, placing the focus on the hier-
archic multi-dimensional activity of the renin angiotensin 
system (RAS) [1]. Angiotensin enzyme (ACE) cleaves 
Ang II from Ang I, hence increasing Ang II , which can 
be then transformed into Ang III and IV. Angiotensins are 
vasoconstrictor hormones that increase blood pressure. 
ACE2 catalyses Ang II, generating Ang (1-7), a vasodila-
tor agent that features antioxidant and anti-inflammatory 
effects; ACE2 metabolizes Ang I into Ang (1-9) which 
performs a protective function on the heart, the vessels, 
and possibly the kidneys; while ACE, which actually de-
termines the Ang II production results in the degradation 
of Ang (1-7) [2,3,5,6]. Based on this simultaneous mosaic of 
processes, ACE inhibitors decrease the production of Ang 
II, and increase the Ang (1-7) in the system. With regards 
to Covid-19, as ACE inhibitors compromise the levels of 
Ang II, they reduce the concentrations of “A Disintegrin 
And Metalloprotease 17” (ADAM17) which is normally 
promoted by Ang II. ADAM17 can cleave ACE2 from 
the cellular membrane, shedding it into body fluids, thus 
restricting the viral S proteins’ fusion with ACE2 recep-
tors, consequently, limiting infection [6,7]. The ADAM17 
cleavage of ACE2 that can be potentially beneficial to 
suppressing the entrance and spread of the virus, is an 
antagonist to the “type II transmembrane serine protease” 
(TMPRSS2) which cleaves both the ACE2 receptor and 
the viral S proteins, preparing them to fit into each other, 
hence facilitating the ominous proliferation of Covid-19 [8]. 
This priming action of TMPRSS2 is necessary for the S/
ACE2 fusion that commences the viral advancement into 
the body. 
Ang II is functional in upregulating ADAM17 that is 
involved in the ACE2 shedding thus restricting Covid-19 
access into the cell; however, Ang II increases inflamma-
tion, oxidative stress and has been associated with athero-
sclerosis [9]; ACE2 catalyses Ang II, acting as a protective 
mechanism against the blood pressure increase induced 
by Ang II that would otherwise be deleterious to diseases 
such as hypertension, diabetes, and cardiovascular illness 
[10]. ACE2 receptors protect the lungs from pulmonary va-
soconstriction and remodelling, they prevent myocardial 
hypertrophy and high blood pressure; yet, by the same to-
ken, they serve as a Covid-19 gateway, exposing the body 
to the deleterious effects of the virus. Ang II increases 
pulmonary edema and vascular permeability that can re-
sult in ARDS; it induces atherosclerosis, hypertension and 
possible heart failure; yet it is involved in the shedding of 
ACE2 receptors via ADAM17 which ultimately reduces 
the chances of viral entry. The lethal effects of SARS-
COV-2 are more pronounced in pre-existing cardiac and 
pulmonary disorders, spotlighting the dualistic function of 
both Angiotensin II and ACE2 receptors that can be both 
an advantage and a disadvantage, rendering treatment in-
surmountable when SARS-CoV-2 is combined with dys-
functional vital organs.
3. The Complex Testimony of Human Tissues
SARS-CoV-2 affects the upper respiratory track with flu-
like symptoms, and the lower respiratory system by symp-
toms including difficulty breathing that may evolve into 
pneumonia or the Acute Respiratory Distress Syndrome 
(ARDS). Counterintuitively, the lungs do not encapsulate 
the greatest multitude of ACE2 receptors. The analysis 
of 31 normal human tissues revealed that adipose tissue, 
heart, testes, kidneys and small intestines had the highest 
ACE2 expression, rendering these organs the primary 
Covid-19 targets, representing the most vulnerable points 
of viral entry. The lungs, adrenal gland, bladder, liver and 
colon manifest a moderate ACE2 expression, while the 
muscle, the brain, blood vessels, spleen and bone marrow 
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evince the lowest ACE2 expression [11,12]. These investiga-
tors also explored male, female, young and old immune 
cells including (1) B cells, lymphocytes that develop into 
plasma cells producing antibodies; (2) natural killer cells 
(NK); (3) CD8+ cells which include cytotoxic T cells that 
specifically target viral infections; and (4) interferons, that 
represent proteins designed to inhibit viral replication, 
as well as T cells’ suppressors, designed to restrain an 
overreactive immune system. Males’ ACE2 expression in 
the lungs, thyroid, liver, colon, kidney, stomach and pan-
creas was linked with increased levels of B, NK, CD8+ T 
cells and interferons. On the other hand, females’ ACE2 
expression in the lungs and thyroid was associated with 
decreased levels of B, NK, CD8+ T cells. Increased ACE2 
expression in the female heart tissues was accompanied 
by increased B, NK, CE8+ T cells and Interferons, unlike 
male heart tissues, where ACE2 receptors and immune 
cells featured a negative correlation. ACE2 receptors in 
the kidneys, skin, stomach, and adipose tissue were as-
sociated with increased levels of immune cells in both 
sexes. ACE2 receptors were positively correlated with 
the lung tissues of older individuals over 45 years and 
negatively correlated with the lung tissues of younger 
individuals under 45 years of age. These results reflect a 
male vulnerability in terms of the positive ACE2/immune 
cells’ correlation with the lungs and thyroid tissues, and 
a disadvantage for females regarding the positive ACE2/
immune cells correlations with the heart tissues. The re-
maining tissues’ ACE2/immunity correlations appeared 
to be similar in both sexes. The positive ACE2/immunity 
may signify the eventual mushrooming of the overstated 
immune response, preluding the lethal consequences of 
the cytokine storm, a process during which lymphocytes, 
leukocytes, interferons and NK cells spin out of control in 
an overly aggressive attack against the virus that causes 
injury to the vital organs. The positive ACE2/immunity 
correlations in male lungs, testes and thyroid tissues, and 
older individuals’ lung tissues when compared to females 
and younger people respectively, may explain the higher 
SARS-COV-2 mortality rates among males and the eldest 
[11,12,13]. However, the higher correlation between ACE2 
receptors and immune cells in female heart tissues, as 
well as the fact that such positive correlations are equiv-
alent in both males’ and females’ kidneys, skin, stomach, 
and adipose tissue, warns against reaching the conclusion 
that women are indiscriminately less susceptible to the 
disease. Therefore, a thorough medical evaluation of all 
vital organs is necessary in evaluating female prognosis to 
Covid-19. More research focused on human tissues’ anal-
ysis from SARS-COV-2 patients may be necessary to fur-
ther elucidate the molecular interactions between ACE2 
receptors and the complex network of immune activity. 
4. The Mechanics of the Cytokine Storm 
Cytokine storm reflects a persistent immune response, 
defensively propelled to annihilate the virus, that blindly 
perseveres, rampaging the infected vital organs with lethal 
consequences [14,15]. 
Cytokines are pleiotropic, multifunctional bio-commu-
nication agents composed by diverse, yet interconnected 
entities, including: 1. Interferons (INFs) which regulate 
immune activity and are classified into I, II, and II sub-
types; INFs type I (IFN-αs, IFN-β, IFN-ω, IFN-κ, and 
IFN-τ) are crucial in eliciting immune responses against 
viral infections [16,17]. 2. Interleukins (IL) which are vital in 
stimulating the immune system; they are involved in the 
proliferation, differentiation and survival of leukocytes, 
otherwise known as white blood cells (WBCs). Interleu-
kin-2 (IL-2) is a signalling molecule that has been used 
to treat cancer, while Interleukin-3 (IL-3) has a protective 
function regarding the survival of macrophages and mast 
cells, and a preventive one against cellular apoptosis 
[18]. Interleukins have both pro- and anti-inflammatory 
properties. Interleukins-1a and 1b (IL-1a and IL-1b) are 
proinflammatory. IL-6 is both a pro-inflammatory cyto-
kine and an anti-inflammatory myokine. IL-8 in involved 
in elevating inflammation [19]. IL-10 is largely accepted 
as an anti-inflammatory cytokine [20]. 3/ Chemokines 
which are mostly pro-inflammatory, recruit leukocytes 
and other immune cells, like neutrophils and monocytes/
macrophages to attack viral entities; leukocytes demon-
strate a positive chemotaxis - a Greek work that reflects 
a chemically driven movement towards a stimulus. Leu-
kocytes shift from blood vessels towards, and into bodily 
tissues initiating inflammation. Chemokines are primarily 
classified into CXC, CC, C, and CX3C subtypes
 [21]. 4. 
Colony-stimulating factors (CSFs) activate the genesis of 
hematopoietic progenitor cells (HPCs), and are closely as-
sociated to inflammation via an intertwined network that 
features IL-1 and the tumour necrosis factors (TNF) [22]. 
5. Tumour Necrosis Factor (TNF) stimulates cytotoxic T 
lymphocytes (CTL), or otherwise known as T-killer cells, 
or CD8+ T-cells. TNF is a protagonist in the emergence of 
the cytokine storm and has been associated with chronic 
inflammation [23,24]. 
IL-1b is one of the central cytokines driving the lungs’ 
proinflammatory processes [25]. The lungs’ inflammatory 
condition provokes renal epithelial cell apoptosis and 
eventual renal dysfunction [26]. This happens as inflamma-
tion overflows from the lungs into the circulation, igniting 
systemic sepsis where TNF, IL-1b and IL-8 are eventu-
ally accompanied by a more substantial increase of IL-6, 
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followed by the anti-inflammatory cytokine IL-10. This 
sequence suggests that IL-6 is stimulated by TNF and IL-
1b which are manifested during the earlier stage of the 
infection [27,28]. The clinical manifestations of the cytokine 
storm appear to resemble a sepsis syndrome, or a System-
ic Inflammatory Response Syndrome (SIRS), induced by 
the host’s dysregulated response to infection. This may 
be partly genetically determined [29], while a sedentary 
lifestyle that accumulates adiposity and instigates inflam-
mation, may be a major contributor to immune aberration 
evoking the cytokine storm. Interleukins (IL-1, IL-2, IL-6, 
IL-8) and TNF, along with the inflammatory marker C-Re-
active Protein (CRP) are prominent in both subcutaneous 
and visceral adipose tissue, increasing the probability of 
Covid-19 infection, due to the abundance of ACE2 recep-
tors in adipose tissue, while exposing the organism to the 
cytokine storm, due to the pre-existing elevated inflamma-
tory condition [30-37]. 
Health is based on immune homeostasis which depends 
on a balance between proinflammatory cytokines and their 
inhibitors. For example, TNFR1 is the inhibitor of TNF, 
and IL-1RA is the inhibitor of IL-1b [38]. The disturbance 
of this balance is followed by the flaring of the cytokine 
storm. It is unclear if the immune cells can no longer 
distinguish between the virus and the infected tissues, or 
whether immune efficiency has deteriorated. Autopsies 
reveal minimal lymphocytes and neutrophils, yet a rel-
atively larger number of macrophages, whose primary 
function is to engulf foreign substances and cellular debris 
[39]. However, an autopsy depicts a biological landscape 
after the war against the virus is over, and may not repre-
sent the processes occurring during the battle. Possibly, 
the excessive effort to overcome the virus depletes energy 
in the form of Adenosine Triphosphate (ATP), promoting 
lymphocytes’ and neutrophils’ apoptosis [40]. Energy de-
pletion, however, does not accurately describe the entire 
process of why and how the immune activity turns against 
itself during the cytokine storm.
Initially, cytokines regulate an innate or non-specific 
line of immune defence. This evolves into the adaptive 
immune response that focuses on the specific virus, a 
critical switch largely controlled by cytokines and chemo-
kines. The cytokine storm is either the result of a) a defi-
cient initial response; b) an inadequate switch between the 
innate and adaptive defences, hence compromising viral 
identification; or c) a series of errors during the adaptive 
stage, obscuring immune ability to distinguish between 
self and non-self, attacking and rampaging the vital organs 
of the host. A number of investigators have postulated that 
insufficient production of Interferon (INF) type I can im-
pair immune innate action [41,42,43]. A recent review suggests 
that coronavirus is designed to hinder the critical process 
of viral recognition, and suppress the production of IFN 
type I, ultimately inhibiting the emergence of the adaptive 
immune response [44]. IFN type I was reportedly lower in a 
patient with poor prognosis and outcome [45]. 
The Interferon-induced proteins 2 and 10 chemokines 
(CXCL2 and CCL10) appear to be associated with disease 
severity, and there is evidence that patients with elevated 
CXCL10 have a larger number of fatalities [46,47]. Addi-
tionally, there is evidence that severely ill patients are 
deficient in the human leukocyte antigen (HLA) system 
of proteins which are recorded by the major histocompat-
ibility complex (HMC) gene. Additionally, they present 
defects related to the Immunoglobulin (IG) gene that 
regulates antigen receptors of the B cells. B cells secrete 
antibodies which target both bacteria and viruses, unlike 
T cells that can only recognize viral antigens [48]. HMC 
genes that encode many proteins involved in T cells an-
tigens that are active during the adaptive response, are 
upregulated in recovered patients but not in deteriorated 
ones. HMC genes are essential for the adaptive immune 
response, therefore, possibly the transition from the innate 
to the adaptive immune response may be flawed. As a 
result the immune target remains non-specific, with com-
promised recognition of the actual virus, resulting in an 
indiscriminate general attack that involves the tissues of 
vital organs with inevitable deleterious circumstances [49,50]. 
5. Methods to Inhibit Viral DNA Replication
As previously stated Nucleocaspic (N) proteins are instru-
mental in the viral RNA replication and transcription that 
is facilitated by the RNA-dependent RNA polymerase 12 
(RdRp), or otherwise known as non-structural protein 12 
(nsp12) in collaboration with the non-structural proteins 
nsp7 and nsp8. Nsp12 is the primary target of Remdesivir, 
a nucleotide analogue (NA) antiviral inhibitor that has re-
cently gained popularity in the treatment of SARS-CoV-2 
by inhibiting viral RNA replication [51-57]. Clinical research 
found a statistically significant advantage of Covid-19 
patients receiving a 5-day Remdesivir course vs standard 
care, but no difference between the 5- and 10-day Rem-
desivir courses [58]. However, a data analysis shows only 
a small clinical improvement between the 5-day / 10-day 
Remdesivir groups when juxtaposed against the standard 
care group. From the 193 patients who received a 10-
day Remdesivir course, 2 died and one required invasive 
mechanical ventilation, while 0 needed non-invasive 
ventilations. From the 191 patients who received a 5-day 
Remdesivir course, 0 died or required invasive mechani-
cal ventilation, while 5 needed non-invasive ventilation. 
From the 200 standard care patients, 4 died, 4 required 
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invasive mechanical ventilation, and 7 required non-in-
vasive ventilation. Subsequent evidence with 1,300 par-
ticipants revealed that Remdesivir may speed up clinical 
improvement and reduce fatalities in severely ill patients. 
Overall, most current research provides low certainty, and 
a weak recommendation for Remdesivir in the treatment 
of Covid-19 [59-62]. 
6. Protective Methods
The extensive person-to-person transmission of Covid-19 
by asymptomatic individuals or those at the initial stages 
of the disease has driven the World Health Organization 
(WHO) to reverse their original recommendation that did 
not require face coverings [63-68]. Wearing masks can pro-
tect the public from those who have already contracted the 
virus, while being a successful prophylactic measure in 
reducing the viral load when one is near infected individ-
uals [69,70,71]. Social models emerging from Taiwan, China 
and Hong Kong where a large part of the population wears 
masks have demonstrated both a lower infection and mor-
tality rate, unlike countries like the USA where not wear-
ing a mask is considered as a right to personal freedom 
[72,73,74]. Hygiene and social distancing are globally accept-
ed as additional protective methods against Covid-19.
7. Capitalize on Wellbeing
A retrospective clinical trial on 150 Covid-19 patients 
demonstrated that Visceral adiposity (p=0.032 p<0.05), 
age (p=0.009 p<0.01) and inflammation measured by 
C-reactive protein (CRP - p<0.0001), were positively cor-
related with poor prognosis and elevated mortality rates [75]. 
Another clinical study used computer tomography (CT) to 
determine the presence of Visceral Adipose Tissue (VAT) 
in Covid-19 infected patients. BMI did not distinguish be-
tween patients in the normal ward and Intensive Care Unit 
(ICU) with or without mechanical ventilation. In fact the 
ICU patients without mechanical ventilation had a slightly 
higher BMI. ICU patients that did not required mechani-
cal ventilation manifested larger amounts of subcutaneous 
fat; however, the most severely ill ICU patients that re-
quired mechanical ventilation were distinguished by their 
accumulated VAT. These investigators concluded that VAT 
may be a possible predictor of exacerbated symptomatol-
ogy and poor prognosis after contracting Covid-19 [76]. 
These results were confirmed by another CT study exam-
ining hepatic steatosis associated with visceral fat, as well 
as epicardial adipose tissue (EAT) in younger Covid-19 
patients under 40 years of age, that classified VAT as one 
of the primary risk factors of viral vulnerability and dis-
ease severity [77]. 
VAT has a higher expression of ACE2 receptors, 
which, as previously noted, represent the entry points of 
Covid-19, in contrast to muscle tissue that has the lowest 
expression of ACE2 receptors. Therefore, any method that 
reduces VAT, utilizing it as an energy source to increase 
muscle, can serve as a protective and preventive method 
to safeguard health during this pandemic. VAT generates 
more fatty acids, angiotensinogen, and interleukin-6 that 
can act as a proinflammatory cytokine, than subcutaneous 
adipose tissue (SAT) [78]. Glucose and fatty acids metab-
olism provide the energy both for the basal metabolic 
processes that sustain life during rest, and the increased 
demand for energy during exercise, where myokines 
like Insulin Growth Factor-1 (IGF-1), Fibroblast Growth 
Factor2 (FGF2), interleukins-6 (IL-6) and IL-7 are in-
volved in muscle hypertrophy [79,80]. Experiments where 
artificially elevated free fatty acids were added during 
sustained physical activity found that the metabolic pro-
cess initially used carbohydrates in the first 15 minutes, 
decreasing glycogen by 50%, and increasing fat oxidation 
by 15% after 30 minutes [81,82]. Fat metabolism reflects 
a complex process that commences with the release of 
free fatty acids (FFA) from the adipose tissue, which are 
transferred across the membranes of muscle cells, where 
they bind with protein receptors in the cytoplasm, with 
the mitochondria being the final destination, where the 
oxidation process, i.e. burning fat via oxygen takes place; 
this results in the release of electrons, which in turn push 
protons to mobilize the energy production process by 
spinning the ATPace synthase anabolic enzyme clockwise, 
to add a phosphate to Adenosine Diphosphate (ADP), via 
the transmembrane proton gradient, to compose Adenos-
ine Triphosphate molecules of energy [83-88]. 
Growth Hormone (GH) appears to be instrumental in 
reducing visceral fat on the basis of a 12 month computed 
tomography (CT) clinical trials that administered recom-
binant human GH to 40 postmenopausal women, demon-
strating reduced visceral fat tissue upon completion [89]. 
Relatively to SAT, VAT secretes less anorexic hormone 
leptin. Although a clinical trial in Europe demonstrated a 
high correlation between leptin and VAT [90], other studies 
with Asian men and African American women indicated 
that leptin is associated with overall fat rather than VAT 
specifically. VAT appears to be a reliable predictor of 
insulin sensitivity, elevated levels of triglycerides and in-
hibited high density lipoproteins (HDL) [91,92]. VAT is also 
associated with triiodothyronine (T3) and the identifier of 
atherosclerosis, pulse wave velocity (PWV) [93].
Weight management solutions including lasers and RF 
primarily address subcutaneous fat reduction with no ev-
idence of increased fitness; additionally, there are several 
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reports of eventual escalated inflammation following some 
of these procedures [94-99]. Pre-existing inflammation can 
potentially exacerbate the deleterious immune response 
termed “cytokine storm” that is detected in Covid-19 se-
vere cases; therefore, inflammation inducing procedures 
may be counterproductive and conceivably dangerous. 
Physical fitness has been deemed a health enhancing solu-
tion by a number of research projects [100-108]. On the other 
hand, there is evidence that exercise may induce asthma 
that usually exacerbates Covid-19 symptomatology, or 
provoke an inverse cortisol/testosterone relationship, 
while supressing the anorexic hormone leptin, thus in-
creasing food consumption [109-114]. Recent studies report 
an advantage with an exercise alternative method invented 
in London University that results in hormonal balance, 
and enhanced wellbeing as measured by statistically sig-
nificant decreases of visceral fat, inflammation, CRP, BMI 
and Triglycerides, juxtaposed by optimal increases of 
skeletal muscle mass, Free T3, IGF-1 and HDL [115-125]. We 
combined some of the data presented in these studies and 
analysed the results with ANOVA for repeated measures.
8. Data Results Analysis
The visceral fat decrease and skeletal mass increase of 29 
patients, 20 females and 9 males with an average BMI of 
29.9 are shown on Table 1. Table 2 reflects the results of 
the same patients indicating a statistically significant in-
crease in the anorexic hormone leptin contrasted by an op-



























F/ 48 DiabetesHyperphagia 31.2 29.3 6.1% 142.65 119.42 -16.28% 12.74 14.66 +15.07%
F/ 54 Diabetes Hyperphagia 30.4 28.6 5.9% 138.54 112.30 -18.94% 11.45 12.95 +13.10%
F/ 56 PrediabetesHyperphagia 31.6 29.9 5.37% 144.23 121.12 -23.11% 12.66 14.76 +6.58%





26.8 24.9 7.1% 104.38 89.23 -14.51% 11.99 14.27 +19.01%





29.5 25.9 12.2% 119.67 98.66 -17.55% 11.32 12.60 +11.30%
F/ 50 Hyperphagia 27.3 25.3 7.3% 117.80 95.64 -18.81% 11.04 13.96 +26.45%
F/ 55 PrediabetesHyperphagia 27.1 24.8 8.5% 98.77 81.32 -17.66% 12.30 13.94 +13.33%
F/ 49 Hyperphagia 29.5 26.3 11.5% 121.63 105.24 -13.47% 12.15 13.93 +14.65%
M / 39 Hyperphagia 33.8 29.4 14.9% 139.30 93.80 -32.66% 36.40 43.80 +20.3%
M / 40 Hyperphagia 29.6 25.7 13.2% 102.20 69.30 -32.19% 30.30 38.60 +27.39%
F / 39 26.1 23.2 11.1% 93.50 58.30 -37.64% 18.40 27.00 +46.79%
F / 41 25.9 22.7 12.4% 85.50 61.40 -28.30% 17.00 26.80 +57.64%
M / 40 24.8 22.4 9.7% 76.40 48.80 -36.12% 37.80 44.80 +18.5%
M / 42 Hyperphagia 28.6 24.7 13.6% 118.60 89.30 -24.70% 29.40 38.30 +30.27%
F / 48 27.33 23.8 12.9% 98.80 70.60 -28.54% 17.20 26.80 +55.81%
F / 43 Hyperphagia 29.4 26.2 10.9% 102.70 77.30 -24.73% 19.80 28.80 +45.45%
M / 39 Hyperphagia 33.2 30.5 8.1% 145.30 104.34 -28.18% 29.80 37.22 +25.89%
F / 42 28.9 24.7 14.5% 109.80 74.67 -31.99% 17.95 26.63 +48.35%
F / 42 29.7 25.7 13.5% 128.97 113.14 -12.27% 27.65 30.87 +11.64%
M / 36 Hyperphagia 33.3 26.9 20.1% 131.20 98.53 -24.9% 33.30 39.60 +18.91%
M / 39 Hyperphagia 34.2 27.3 20.2% 119.67 96.62 -19.26% 36.40 39.80 +9.34%
M / 43 Hyperphagia 32.8 26.4 19.5% 99.56 79.34 -20.22% 27.13 31.95 +17.75%
M / 35 29.6 25.9 14.2% 121.68 104.29 -14.29% 17.57 23.32 +32.72%
F / 42 Hyperphagia 35.2 27.4 22.2% 129.73 109.28 -15.76% 20.16 24.53 +21.67%
F / 45 Hyperphagia 33.8 26.1 22.8% 109.63 95.85 -12.56% 16.89 22.85 +35.28%
F / 49 Hyperphagia 32.6 27.8 14.7% 122.66 87.85 -28.38% 20.73 25.52 +23.11%
F / 38 28.9 24.5 15.2% 134.64 112.80 -16.22% 16.83 23.18 +37.73%
BMI DE-
CREASE 29.9 26.1 12.70%
Mean Average Visceral Fat % 
Decrease -22.44%
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Table 2. Blood Plasma Results of 29 Subjects with an average BMI of 29.9 on Leptin (Reference Ranges of Leptin 
Levels According to Body Mass Index, Gender and Development Stage [Table 3]. Blood Plasma Results on Ghrelin for 























F/ 48 DiabetesHyperphagia 31.2 21.45 27.44 12.2-67.5 +27.92% 483 414 340-450 -14.28%
F/ 54 Diabetes Hyperphagia 30.4 14.63 18.08 10.6-58.3 +23.58% 488 463 340-450 -5.13%
F/ 56 Prediabetes Hyperphagia 31.6 10.67 13.66 12.2-67.5 +28.02% 462 398 340-450 -13.85%





26.8 12.34 15.12 5.9-32.4 +22.53% 498 453 340-450 -9.03%





29.5 20.66 21.45 9.1-50.4 +3.82% 387 364 340-450 -5.94%
F/ 50 Hyperphagia 27.3 11.65 15.43 6.8-37.5 +3.82% 401 389 340-450 -2.99%
F/ 55 Prediabetes Hyperphagia 27.1 15.24 18.56 6.8-37.5 +21.78% 465 432 340-450 -7.09%
F/ 49 Hyperphagia 29.5 18.54 19.82 9.1-50.4 +6.90% 474 439 340-450 -7.38%
M / 39 Hyperphagia 33.8 7.38 7.84 14.1-78.2 +6.2% 683 614 340-450 -10.1%
M / 40 Hyperphagia 29.6 6.25 7.03 9.1-50.4 +12.48% 588 576 340-450 -2%
F / 39 26.1 12.43 13.22 5.9-32.4 +6.35% 612 584 340-450 -4.5%
F / 41 25.9 11.98 12.09 5.1-28.0 +0.9% 599 543 520-700 -9.34%
M / 40 24.8 5.53 5.94 4.4-24.2 +7.41% 602 553 520-700 -8.13%
M / 42 Hyperphagia 28.6 6.42 6.97 7.9-43.5 +8.56% 603 576 340-450 -4.47%
F / 48 27.33 10.87 11.84 6.8-37.5 +8.92% 687 612 340-450 -10.9%
F / 43 29.4 9.89 10.54 9.1-50.4 +3.53% 623 565 520-700 -9.30%
M / 39 Hyperphagia 33.2 5.47 6.01 16.4-90.5 +4.1% 589 532 340-450 -9.71%
F / 42 28.9 9.99 10.83 7.9-43.5 +6.4% 634 513 340-450 -19.08%
M / 36 29.7 3.69 3.98 9.1-50.4 +7.86% 687 602 340-450 -12.37%
M / 39 Hyperphagia 33.3 4.43 4.98 16.4-90.5 +9.78% 695 634 340-450 -8.77%
M / 43 Hyperphagia 34.2 5.62 6.22 19.0-105. +10.68% 598 552 340-450 -7.69%
M / 35 Hyperphagia 32.8 6.15 6.83 14.1-78.2 +11.05% 629 587 340-450 -6.68%
F / 42 29.6 9.16 9.74 9.1-50.4 +6.33% 577 542 340-450 -6.06%
F / 45 Hyperphagia 35.2 5.23 6.09 22.-121 +16.44% 659 613 340-450 -6.99%
F / 49 Hyperphagia 33.8 7.22 8.17 16.4-90.5 +13.15% 644 617 340-450 -4.19%
F / 38 Hyperphagia 32.6 12.34 13.22 14.1-78.2 +7.13% 569 536 340-450 -5.79%











Table 3. Leptin Ranges by Body Mass Index ng/mL
BMI Range BMI Range
11 0.7 - 3.6 24 4.4 -24.2
12 0.8 - 4.2 25 5.1 -28.0
13 0.9 - 4.8 26 5.9 -32.4
14 1.0 - 5.6 27 6.8 -37.5
15 1.2 - 6.5 28 7.9 -43.5
16 1.4 - 7.5 29 9.1 -50.4
17 1.6 - 8.7 30 10.6 -58.3
18 1.8 - 10.0 31 12.2 -67.5
19 2.1 - 11.6 32 14.1 -78.2
20 2.4 - 13.4 33 16.4 -90.5
21 2.8 - 15.6 34 19.0 - 105.0
22 3.3 - 18.0 35 22.0 - 121.0
23 3.8 - 20.9 36 25.4 - 141.0
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timal decrease in the orexigenic hormone ghrelin. Table 3 
depicts leptin ranges in relation to body mass index. Table 
4 shows the inflammation reduction as measured by CRP 
and the cortisol decrease of 10 females with an average 
BMI of 32.91 and at least one medical condition. 
Table 5 reflects the results of 30 subjects, 22 females 
and 8 males with an average BMI of 32.96 on HDL and 
Triglycerides. Thirteen out of these subjects were diabet-
ics and thirteen were prediabetics.
Table 6 reflects the results of 20 subjects, 15 females 
and 5 males on Free T3 and IGF-1. 
Table 7 shows the significance values for all variables 
after the data was analysed with ANOVA for repeated 
Table 4. Blood Test Results on 10 Female Subjects with an average BMI of 32.9 for C-reactive protein (CRP) and Cor-
tisol


















Female 56 Diabetes Fatty Liver 32.6 1.56 1.02 <1.00 18.44 15.66 3.09-25.0
Female 52 Prediabetes Fatty Liver 36.5 1.09 1.06 <1.00 21.89 20.12 3.09-25.0
Female 49 Hypertension Hypothyroidism 28.6 2.31 1.15 <1.00 24.98 18.47 3.09-25.0















30.9 1.04 0.86 <1.00 9.67 8.23 3.09-25.0
Female 61 Hypertension Fatty Liver 32.7 1.08 0.74 <1.00 14.76 10.65 3.09-25.0





33.8 2.11 1.03 <1.00 21.28 17.24 3.09-25.0
Mean Average CRP % Decrease -36.87 mg/dL Mean Average Cortisol % Decrease -17.47% μg/dL
Notes: CRP: <1.0 mg/dL. Low cardiovascular risk according to AHA/CDC
CRP: 1.0-3.0 mg/dL Average cardiovascular risk according to AHA/CDC
CRP: >3.0-10.0 mg/dL High cardiovascular risk according to AHA/CDC
Table 5. Blood Test Results on 30 subjects
Gender/ 















Trigly cerides Normal 
Range 
mg/dL
F/56 32.6 Diabetes Fatty Liver 53 61 >60 144 137 <150
F/52 36.5 Prediabetes Fatty Liver 39 57 >60 169 146 <150
F/49 28.6 Hypertension Hypothyroidism 61 79 >60 129 114 <150










43 51 >60 173 159 <150
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Gender/ 






















63 76 >60 153 139 <150
F/61 32.7 Hypertension Fatty Liver 52 71 >60 175 148 <150





38 52 >60 182 157 <150
F/45 34.4 Diabetes 32 39 >60 203 158 <150
M/69 28.5 Diabetes 35 47 >60 215 128 <150
M/46 35.3 Diabetes 28 37 >60 230 153 <150
F/50 38 Diabetes 49.6 53 >60 86.7 84.3 <150
F/49 40.5 Diabetes 34.5 38 >60 103 88 <150
F/46 36.2 Diabetes 32 39 >60 287 176 <150
M/48 38.5 Diabetes 29 41 >60 266 147 <150
F/44 38.2 Diabetes 30 35 >60 283 189 <150
F/43 27.7 Prediabetes 36 42 >60 294 197 <150
F/27 35.4 Prediabetes 36 48 >60 192 126 <150
F/63 30.7 Prediabetes 45 47 >60 155 117 <150
F/24 33.9 Prediabetes 45 52 >60 88 86 <150
F/30 32.0 Prediabetes 37 46 >60 156 124 <150
F/45 30.1 Diabetes 33 40 >60 225 179 <150
F/47 25.1 Diabetes 31 41 >60 237 188 <150
M/45 29.4 Diabetes 41 45 >60 112 105 <150
M/82 34.5 Diabetes 26 38 >60 97 94 <150
M/15 31.8 Prediabetes 36 42 >60 187 132 <150
M/58 28.9 Prediabetes 43.1 46.8 >60 141 136 <150
M/46 30.6 Prediabetes 52.3 56 >60 262 158 <150
BMI 
Average 32.96 40.88 50.22
22.84% Increase 180.09 139.25 40.84% Decrease
Note: High-Density Lipoprotein (HDL) Normal Range: Men > 60 mg/dL; Women > 60 mg/dL High-Density Lipoprotein (HDL) At Risk: Men: <40 
mg/dL; Women < 50 mg/dL



























M/32 None known 25.97 30.35 15.08-32.5 +16.86% 2.98 4.22 2.63-5.7 +41%
M/35 None known 23.98 31.12 15.08-32.5 +29.77% 3.69 4.98 2.63-5.7 +34.95%
F/36 None known 16.33 20.75 11.25-28.8 +27.06% 4.77 5.37 2.63-5.7 +12.5%
F/35 None known 15.14 19.21 11.25-28.8 +26.88% 4.56 5.31 2.63-5.7 +16.44%
M/37 None known 22.27 28.11 15.08-32.5 +26.22% 4.15 5.47 2.63-5.7 +31.80%
M/39 None known 26.98 30.52 15.08-32.5 +11.80% 3.29 4.86 2.63-5.7 +47.7%
F/39 None known 15.86 21.08 11.25-28.8 +32.91% 4.36 5.64 2.63-5.7 +29.35%
F/32 None known 18.55 23.50 11.25-28.8 +26.68% 3.66 4.79 2.63-5.7 +30.87%
M/36 None known 24.56 31.34 15.08-32.5 +27.60% 3.19 4.12 2.63-5.7 +29.15%
F/33 None known 19.34 25.66 11.25-28.8 +32.67% 4.09 5.12 2.63-5.7 +25.18%
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measures. Results yielded highly statistically significant 
results. Visceral fat decrease was accompanied with in-
creased skeletal muscle mass. IGF-1, Free T3 and Leptin 
increased within the normal range, while cortisol and 
ghrelin decreased but without descending into abnormal-
ity. These results demonstrated a centralized tendency 
towards hormonal balance and optimal appetite regulation 
resulting by a healthy proportional interaction between the 
anorexic hormone leptin, juxtaposed by the relatively sup-
pressed concentrations of the orexigenic hormone ghrelin, 
combined with reduced cortisol that is known to provoke 
stress-eating behaviours. Elevated HDL was accompanied 
by diminished triglycerides. 
9. Discussion
The immune collapse during the cytokine storm follow-
ing Covid-19 invasion that has infected over forty-three 
million individuals worldwide, resulting in over a million 
deaths, brings to mind the unpredictable defeat of the gi-
ant during the David and Goliath battle. 
The virus enters the system via ACE2 receptors which 
catalyze Angiotensin II (Ang II). Excess Ang II increas-
es blood pressure that is deleterious to diseases such 
as hypertension, diabetes, and cardiovascular illness, 
which represent the pre-existing conditions with elevat-



























F/ 48 DiabetesHyperphagia 12.23 14.17 11.25-28.8 +14.86% 2.19 2.88 2.63-5.7 +31.50%
F/ 54 Diabetes Hyperphagia 11.65 12.33 11.25-28.8 +5.83% 2.34 2.76 2.63-5.7 +34.95%
F/ 56 PrediabetesHyperphagia 11.17 12.79 11.25-28.8 +14.50% 1.98 2.64 2.63-5.7 +33.33%





12.27 14.32 11.25-28.8 +7.65% 2.32 2.89 2.63-5.7 +21.98%





10.21 11.99 11.25-28.8 +17.43% 2.29 2.78 2.63-5.7 +21.39%
F/ 50 Hyperphagia 12.87 14.36 11.25-28.8 +11.57% 2.68 3.29 2.63-5.7 +22.76%
F/ 55 PrediabetesHyperphagia 11.43 12.85 11.25-28.8 +12.42% 2.16 2.59 2.63-5.7 +19.91%







Free T3 % 
Increase
+27%
Table 7. Analysis of Variance Statistical Significance Results on all variable
SS df MS F-Ratio Value p-Value Significance Level
Visceral Fat and Skeletal Mus-










F = 390.074 <0.00001 P<0.00001











F = 779.92202 <0.00001 P<0.00001











F = 148.02771 <0.00001 P<0.00001











F = 136.96899 <0.00001 P<0.00001










F = 130.72807 <0.00001 P<0.00001
Abbreviations: BT: Between Treatments / WT: Within Treatments / E: Error
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increases concentrations of “A Disintegrin And Metal-
loprotease 17” (ADAM17) that can cleave ACE2 from 
the cellular membrane, shedding it into body fluids, thus 
restricting viral access.
Human tissues’ research has revealed a multitude of 
ACE2 receptors in adipose tissue, heart, kidneys, thyroid, 
testes and small intestines with relatively less ACE2 ex-
pression in the muscle, brain, spleen and blood vessels. 
Lungs, liver, adrenal gland, bladder and colon seem to be 
somewhere in between. Investigation of B, NK, CE8+ T 
cells and Interferons in males, females, young and old, 
has shown a greater susceptibility among older individu-
als evidenced by a multitude of immune cells in the lungs. 
Higher ACE2 expression in the testes in addition to other 
tissues increase male vulnerability that is marked by the 
elevated number of certain immune cells in the lungs, thy-
roid, adrenals, liver and colon. In contrast, females present 
a higher positive correlation between immune cells and 
the heart; all other tissues manifest equivalent levels of 
immune cells in both sexes. In other words, there may be 
a Covid-19 preference for males and older individuals, but 
without a safety guarantee for females that may be equally 
susceptible in certain cases.
A literature review of the immune overreaction during 
the cytokine storm suggests a possible imbalance between 
pro-inflammatory cytokines and their inhibitors, a defi-
cient immune response due to insufficient production of 
INF type I, or a dysregulated transition from the non-spe-
cific / innate to the adaptive immunity, that is designed to 
recognize and attack the particular threat, represented in 
this case by Covid-19. Hence, the frenzied immune over-
reaction aimlessly persevering, unable to distinguish self 
from non-self that rampages and injures the body. 
New pharmaceuticals designed to interfere with vi-
ral RNA replication like Remdesivir that targets the 
non-structural protein 12 (nsp12) in collaboration with the 
non-structural proteins nsp7 and nsp8, have had modest to 
moderate clinical outcomes, providing a weak recommen-
dation for Remdesivir in the treatment of Covid-19. 
Protective techniques including, face coverings, social 
distancing and thorough hygiene, as well as prevention 
via fitness, health enhancement and weight management 
are currently the most reliable methods of limiting the 
spread of the pandemic. Visceral adipose tissue (VAT) is 
strongly linked to Covid-19 severely ill patients in ICU 
needing mechanical ventilation, irrespective of BMI 
which does not distinguish between patients in normal 
wards and ICU. VAT has a higher expression of ACE2 
receptors that represent the portals for Covid-19 entry. 
VAT generates more fatty acids, angiotensinogen, and the 
pro-inflammatory interleukin-6 (IL-6). Any method that 
reduces VAT, utilizing it as an energy source to increase 
muscle which features the least ACE2 receptors, therefore 
limiting Covid-19 entry, can serve as a protective and pre-
ventive measure in safeguarding health during this health 
crisis. Lasers and RF primarily address subcutaneous fat 
reduction with no evidence of increased fitness Addition-
ally, a number of studies report escalated inflammation 
following some of these procedures. Physical activity has 
universally accepted benefits, but also a downside by pro-
voking an inverse cortisol/testosterone relationship, while 
supressing the anorexic hormone leptin, thus increasing 
food consumption. Recent research on an effortless exer-
cise intervention presents statistically significant VAT and 
inflammation reduction, juxtaposed by skeletal muscle 
mass increase, along with reduced lipids, cortisol and the 
orexigenic hormone ghrelin; importantly, it also elevates 
Free T3, IGF-1 and the anorexic hormone leptin within 
the normal range, offering an optimal alternative to fast 
efficient fitness. These clinical trials, however, are mostly 
based on small samples, in the absence of imaging tech-
niques that can substantiate their results, warranting the 
need for additional research.
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